Abstract
The aim of this study was to evaluate the antibacterial activity of the licochalcones A (1) and E (2) against drug resistant strains of clinical origin. The results indicate that the licochalcones had a broad inhibitory activity against tested bacteria. Compared to vancomycin and teicoplanin, these compounds provided weaker activity against non-MDR Staphylococcus aureus and Enterococcus but broader activity against MRSA and VRE strains. The results provide promising baseline information for the potential use of 1 and 2 from Glycyrrhiza inflata in the treatment of drug resistant bacterial infections.
